Navigation Links
Amgen To Host Post American Society of Hematology (ASH) Summary Webcast
Date:12/10/2013

THOUSAND OAKS, Calif., Dec. 10, 2013 /PRNewswire/ -- Amgen (NASDAQ: AMGN) and its subsidiary Onyx Pharmaceuticals, Inc. today announced that they will hold a post American Society of Hematology (ASH) summary webcast on Wednesday, Dec. 11, 2013, at 11 a.m. PST. Pablo Cagnoni, M.D., president of Onyx Pharmaceuticals, Inc. and Anthony C. Hooper, executive vice president of Global Commercial Operations at  Amgen, will participate in the call to discuss a brief summary of data presented at ASH. In addition, they will discuss a summary of feedback received from key opinion leaders and the steps Amgen is taking to develop Kyprolis® (carfilzomib) across all lines of therapy to address unmet needs in multiple myeloma patients.

Live audio of the investor call will be simultaneously broadcast over the Internet and will be available to members of the news media, investors and the general public.

The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event. 

About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.

Amgen focuses on areas of high unmet medical need and leverages its biologics manufacturing expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be the world's largest independent biotechnology company, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. 

For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.

CONTACT: Amgen, Thousand Oaks
Ashleigh Koss, 805-313-6151 (media)
Arvind Sood, 805-447-1060 (investors)

(Logo: http://photos.prnewswire.com/prnh/20081015/AMGENLOGO)


'/>"/>
SOURCE Amgen
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Amgen and FDA Agree to Modify Nplate® (Romiplostim) Risk Evaluation and Mitigation Strategy
2. Amgen Presents Final Results from the Largest Phase 3 Open-Label Study Assessing the Safety and Efficacy of Nplate® (Romiplostim)
3. Amgen Announces 2012 First Quarter Dividend
4. Kevin Sharer, Amgen Chairman and CEO, Announces Plan to Retire With Robert Bradway to Become CEO on May 23, 2012; Sharer Will Continue as Chairman of the Board Until End of 2012
5. Amgen to Present at the 30th Annual J.P. Morgan Global Healthcare Conference
6. Amgen Announces Webcast of 2011 Fourth Quarter and Full Year Financial Results
7. Amgen to Acquire Micromet
8. Amgen to Present at the Leerink Swann Global Healthcare Conference
9. Amgen Announces 2012 Third Quarter Dividend
10. Amgen Names Ray Jordan Senior Vice President, Corporate Affairs
11. Amgen To Present At The 24th Annual Piper Jaffray Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... , Dec. 7, 2016  Nordion, a ... General Atomics (GA), welcome today,s award by the ... Security Administration (NNSA) of the Phase II cooperative ... with Nordion and the University of Missouri Research ... funding will support the establishment of a new, ...
(Date:12/7/2016)... India , December 8, 2016 The report "Acrylic Processing ... & Construction, Packaging, Automotive, Consumer Goods) - Global Forecast to 2026", published by ... projected to reach USD 1,173.6 Million by 2026, registering an of CAGR of ... ... MarketsandMarkets Logo ...
(Date:12/7/2016)... 2016  Genprex, Inc. a biopharmaceutical company focused ... today announced that it has retained ICR Healthcare, ... communications and advisory firm, to develop and implement ... combine investor relations, public relations and digital communications ... of Genprex and its lead candidate Oncoprex, which ...
(Date:12/7/2016)... and ANN ARBOR, Mich. , Dec. ... company developing breakthrough immune modulatory medicines, announced today the ... Company,s lead therapeutic candidate, LYC-30937- E nteric C ... debilitating skin disease that is estimated to affect as ... States , with approximately 1.5 - 3 million ...
Breaking Biology Technology:
(Date:6/22/2016)... American College of Medical Genetics and Genomics was once again ... of the fastest-growing trade shows during the Fastest 50 Awards ... Las Vegas . Winners are ... of the following categories: net square feet of paid exhibit ... 2015 ACMG Annual Meeting was ranked 23 out of 50 ...
(Date:6/21/2016)... British Columbia , June 21, 2016 /PRNewswire/ ... appointed to the new role of principal product ... been named the director of customer development. Both ... NuData,s chief technical officer. The moves reflect NuData,s ... teams in response to high customer demand and ...
(Date:6/15/2016)... ALBANY, New York , June 15, 2016 ... published a new market report titled "Gesture Recognition Market ... Trends and Forecast, 2016 - 2024". According to the ... at USD 11.60 billion in 2015 and is ... and reach USD 48.56 billion by 2024.  ...
Breaking Biology News(10 mins):